Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.

scientific article

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.JTHO.2016.12.024
P698PubMed publication ID28093244

P50authorCaicun ZhouQ114358334
P2093author name stringKai Chen
Tao Jiang
Fei Zhou
Xue Wu
Yang W Shao
Xiaoling Tong
Songbing Qin
Wenxiang Shen
P433issue6
P304page(s)e65-e68
P577publication date2017-01-16
P1433published inJournal of Thoracic OncologyQ2448056
P1476titleNovel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.
P478volume12

Reverse relations

cites work (P2860)
Q91762027A "triple whammy" in adenocarcinoma lung
Q89497162Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018
Q61810143Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives
Q49643911Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.
Q92493465Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer
Q60303033Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lung cancer: a meta-analysis of the experimental evidence
Q90429716Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFRL858R/T790M
Q47146662Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer
Q60301224Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report
Q47777525Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
Q38682189Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms
Q57177486Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective
Q61797228Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
Q40989687Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion
Q55191884Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.
Q58750993SOX5 induces lung adenocarcinoma angiogenesis by inducing the expression of VEGF through STAT3 signaling
Q52655063SOX5 predicts poor prognosis in lung adenocarcinoma and promotes tumor metastasis through epithelial-mesenchymal transition.
Q100636214The next tier of EGFR resistance mutations in lung cancer
Q49887956Third generation EGFR TKIs: current data and future directions
Q52332839Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients.
Q88682201Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance

Search more.